Repurposing Nucleoside Analogs for Human Coronaviruses.
COVID-19
Coronaviridae
HCoV-OC43
SARS-CoV-2
antiviral agents
emtricitabine
lamivudine
nucleoside analogs
remdesivir
sofosbuvir
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
16 12 2020
16 12 2020
Historique:
received:
30
07
2020
accepted:
26
10
2020
pubmed:
31
10
2020
medline:
29
12
2020
entrez:
30
10
2020
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) is a serious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or CoV-2). Some reports claimed certain nucleoside analogs to be active against CoV-2 and thus needed confirmation. Here, we evaluated a panel of compounds and identified novel nucleoside analogs with antiviral activity against CoV-2 and HCoV-OC43 while ruling out others. Of significance, sofosbuvir demonstrated no antiviral effect against CoV-2, and its triphosphate did not inhibit CoV-2 RNA polymerase.
Identifiants
pubmed: 33122172
pii: AAC.01652-20
doi: 10.1128/AAC.01652-20
pmc: PMC7927863
pii:
doi:
Substances chimiques
Antiviral Agents
0
Nucleosides
0
Propanolamines
0
ALS 8123
81148-15-4
Sofosbuvir
WJ6CA3ZU8B
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI141327
Pays : United States
Informations de copyright
Copyright © 2020 American Society for Microbiology.
Références
J Pharmacol Pharmacother. 2014 Oct;5(4):278-84
pubmed: 25422576
Antiviral Res. 2020 Mar;175:104712
pubmed: 31935422
Drug Discov Ther. 2020;14(1):58-60
pubmed: 32147628
Antimicrob Agents Chemother. 1992 Mar;36(3):672-6
pubmed: 1320365
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Cancer Commun. 1991 Jul;3(7):207-12
pubmed: 1867954
Clin Pharmacol Ther. 2020 Aug;108(2):188
pubmed: 32350860
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
Int J Infect Dis. 2014 Mar;20:42-6
pubmed: 24406736
J Med Chem. 2017 Jul 13;60(13):5424-5437
pubmed: 28595015
Clin Liver Dis. 2019 Aug;23(3):535-555
pubmed: 31266626
Nat Rev Microbiol. 2019 Oct;17(10):593-606
pubmed: 31341272
Int J Antimicrob Agents. 2020 May;55(5):105951
pubmed: 32234466
J Med Chem. 2019 Feb 28;62(4):1859-1874
pubmed: 30653317
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
Ann Intern Med. 2020 Oct 6;173(7):536-541
pubmed: 32589451
Ann Intern Med. 2020 Jul 21;173(2):JC4
pubmed: 32687756
Vopr Virusol. 2001 Sep-Oct;46(5):40-2
pubmed: 11715709
N Engl J Med. 2020 Sep 3;383(10):994
pubmed: 32649078
J Med Chem. 2015 Feb 26;58(4):1862-78
pubmed: 25667954
J Med Chem. 2017 Mar 9;60(5):1648-1661
pubmed: 28124907
Paediatr Int Child Health. 2020 Jun 25;:1-20
pubmed: 32584199
Life Sci. 2020 May 1;248:117477
pubmed: 32119961
Sci Rep. 2020 Jun 9;10(1):9294
pubmed: 32518317
Virol Sin. 2020 Jun;35(3):272-279
pubmed: 32239446
J Med Chem. 2004 Oct 7;47(21):5284-97
pubmed: 15456273
J Med Chem. 2006 Nov 2;49(22):6614-20
pubmed: 17064080
Antimicrob Agents Chemother. 2019 Aug 23;63(9):
pubmed: 31262759
Cell Rep. 2020 Jul 21;32(3):107940
pubmed: 32668216
Antimicrob Agents Chemother. 2020 Aug 20;64(9):
pubmed: 32631826
Nucleic Acids Res. 1983 Aug 11;11(15):5223-33
pubmed: 6224136
Antiviral Res. 2005 Jun;66(2-3):81-97
pubmed: 15878786
Antimicrob Agents Chemother. 2003 Jan;47(1):244-54
pubmed: 12499198
Curr Opin Virol. 2019 Apr;35:57-62
pubmed: 31125806